Ascites - Pipeline Insight, 2025
Description
DelveInsight’s, “Ascites - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ascites pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ascites: Overview
Ascites is the pathologic accumulation of fluid within the peritoneal cavity. It is the most common complication of cirrhosis and occurs in about 50% of patient with decompensated cirrhosis in 10 years. The development of ascites denotes the transition from compensated to decompensated cirrhosis. Mortality increases from complications such as spontaneous bacterial peritonitis and hepatorenal syndrome. Mortality ranges from 15% in a year to 44% in 5 years. Patients with cirrhotic ascites have a 3-year mortality rate of approximately 50%. Refractory ascites carries a poor prognosis, with a 1-year survival rate of less than 50%. Males have little intraperitoneal fluid, females have approximately 20 mL, depending on the phase of their menstrual cycle. The first abnormality that develops is portal hypertension in the case of cirrhosis. Portal pressure increases above a critical threshold and circulating nitric oxide levels increase, leading to vasodilatation. As the state of vasodilatation becomes worse, the plasma levels of vasoconstrictor sodium-retentive hormones elevate, renal function declines, and ascitic fluid forms, resulting in hepatic decompensation. Through the production of proteinous fluid by tumor cells lining the peritoneum, peritoneal carcinomatosis also can cause ascites. In high-output or low-output heart failure or nephrotic syndrome, effective arterial blood volume is decreased, and the vasopressin, renin-aldosterone, and sympathetic nervous systems are activated, leading to renal vasoconstriction and sodium and water retention.
Diagnostic abdominal paracentesis with appropriate ascitic fluid analysis is crucial for diagnosing the cause of ascites. Initial tests include blood cell count, bacterial culture, and measuring ascitic fluid protein and albumin to calculate the serum-ascites albumin gradient (SAAG). A SAAG greater or equal to 1.1 g/dL predicts portal hypertension, seen in various conditions. Additional tests like LDH, glucose, and amylase are performed based on clinical suspicion. Chest x-ray may show an elevated diaphragm, while ultrasound is sensitive for detecting ascites. CT scans can also detect ascites and masses.
Treatment of ascites is tailored to the underlying cause of fluid retention, aiming to reduce ascitic fluid volume and peripheral edema without depleting intravascular volume. Sodium restriction and diuretics are fundamental in managing ascites. For high-albumin-gradient ascites in cirrhosis, treatment includes alcohol abstinence, limited sodium intake, and diuretics. Specific therapies are essential for liver conditions like autoimmune hepatitis or chronic hepatitis B. Low-albumin-gradient ascites may require therapeutic paracentesis or specific treatments based on the cause. Therapeutic options for refractory ascites include large volume paracentesis, transjugular intrahepatic portosystemic shunt (TIPS), or liver transplantation.
""Ascites- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ascites pipeline landscape is provided which includes the disease overview and Ascites treatment guidelines. The assessment part of the report embraces, in depth Ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ascites Emerging Drugs
Further product details are provided in the report……..
Ascites: Therapeutic Assessment
This segment of the report provides insights about the different Ascites drugs segregated based on following parameters that define the scope of the report, such as:
Ascites: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ascites therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ascites drugs.
Ascites Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Ascites: Overview
Ascites is the pathologic accumulation of fluid within the peritoneal cavity. It is the most common complication of cirrhosis and occurs in about 50% of patient with decompensated cirrhosis in 10 years. The development of ascites denotes the transition from compensated to decompensated cirrhosis. Mortality increases from complications such as spontaneous bacterial peritonitis and hepatorenal syndrome. Mortality ranges from 15% in a year to 44% in 5 years. Patients with cirrhotic ascites have a 3-year mortality rate of approximately 50%. Refractory ascites carries a poor prognosis, with a 1-year survival rate of less than 50%. Males have little intraperitoneal fluid, females have approximately 20 mL, depending on the phase of their menstrual cycle. The first abnormality that develops is portal hypertension in the case of cirrhosis. Portal pressure increases above a critical threshold and circulating nitric oxide levels increase, leading to vasodilatation. As the state of vasodilatation becomes worse, the plasma levels of vasoconstrictor sodium-retentive hormones elevate, renal function declines, and ascitic fluid forms, resulting in hepatic decompensation. Through the production of proteinous fluid by tumor cells lining the peritoneum, peritoneal carcinomatosis also can cause ascites. In high-output or low-output heart failure or nephrotic syndrome, effective arterial blood volume is decreased, and the vasopressin, renin-aldosterone, and sympathetic nervous systems are activated, leading to renal vasoconstriction and sodium and water retention.
Diagnostic abdominal paracentesis with appropriate ascitic fluid analysis is crucial for diagnosing the cause of ascites. Initial tests include blood cell count, bacterial culture, and measuring ascitic fluid protein and albumin to calculate the serum-ascites albumin gradient (SAAG). A SAAG greater or equal to 1.1 g/dL predicts portal hypertension, seen in various conditions. Additional tests like LDH, glucose, and amylase are performed based on clinical suspicion. Chest x-ray may show an elevated diaphragm, while ultrasound is sensitive for detecting ascites. CT scans can also detect ascites and masses.
Treatment of ascites is tailored to the underlying cause of fluid retention, aiming to reduce ascitic fluid volume and peripheral edema without depleting intravascular volume. Sodium restriction and diuretics are fundamental in managing ascites. For high-albumin-gradient ascites in cirrhosis, treatment includes alcohol abstinence, limited sodium intake, and diuretics. Specific therapies are essential for liver conditions like autoimmune hepatitis or chronic hepatitis B. Low-albumin-gradient ascites may require therapeutic paracentesis or specific treatments based on the cause. Therapeutic options for refractory ascites include large volume paracentesis, transjugular intrahepatic portosystemic shunt (TIPS), or liver transplantation.
""Ascites- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ascites pipeline landscape is provided which includes the disease overview and Ascites treatment guidelines. The assessment part of the report embraces, in depth Ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ascites R&D. The therapies under development are focused on novel approaches to treat/improve Ascites.
This segment of the Ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ascites Emerging Drugs
- OCE-205: Ocelot Bio
- SCB-313: Clover Biopharmaceuticals
Further product details are provided in the report……..
Ascites: Therapeutic Assessment
This segment of the report provides insights about the different Ascites drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ascites
- There are approx. 10+ key companies which are developing the therapies for Ascites. The companies which have their Ascites drug candidates in the most advanced stage, i.e. Phase II include, Ocelot Bio.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Ascites: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ascites therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ascites drugs.
Ascites Report Insights
- Ascites Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ascites drugs?
- How many Ascites drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ascites?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ascites therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ascites and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sichuan Clover Biopharmaceuticals
- PharmaIN
- Ocelot Bio
- Biovie
- PharmaIN
- SCB-313
- PHIN-214
- OCE-205
- Terlipressin
- PHIN-214
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Ascites: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Ascites– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Ocelot Bio: OCE-205
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SCB-313: Clover Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Ascites Key Companies
- Ascites Key Products
- Ascites- Unmet Needs
- Ascites- Market Drivers and Barriers
- Ascites- Future Perspectives and Conclusion
- Ascites Analyst Views
- Ascites Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
